{"protocolSection":{"identificationModule":{"nctId":"NCT02806128","orgStudyIdInfo":{"id":"MAISKFE1.0"},"organization":{"fullName":"General Hospital of Shenyang Military Region","class":"OTHER"},"briefTitle":"The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship","officialTitle":"The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship","acronym":"MAISKFE"},"statusModule":{"statusVerifiedDate":"2016-08","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-11"},"primaryCompletionDateStruct":{"date":"2018-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2016-06-10","studyFirstSubmitQcDate":"2016-06-17","studyFirstPostDateStruct":{"date":"2016-06-20","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-01-05","lastUpdatePostDateStruct":{"date":"2017-01-06","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Huisheng Chen","investigatorTitle":"Principal Investigator","investigatorAffiliation":"General Hospital of Shenyang Military Region"},"leadSponsor":{"name":"Huisheng Chen","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Evaluate the effectiveness of the of kallikrein in the different drug frequency for acute anterior circulation cerebral infarction."},"conditionsModule":{"conditions":["Cerebral Infarction"],"keywords":["cerebral infarction","kallikrein","KLK"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":100,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment group","type":"EXPERIMENTAL","description":"Injection of Human Urinary Kallidinogenase for Injection (KLK) three times a day, 14 days .\n\nPatients need to complete laboratory tests within a specified time.","interventionNames":["Drug: Human Urinary Kallidinogenase for Injection"]},{"label":"Control group","type":"EXPERIMENTAL","description":"Injection of Human Urinary Kallidinogenase for Injection (KLK) Once times a day, 14 days .\n\nPatients need to complete laboratory tests within a specified time.","interventionNames":["Drug: Human Urinary Kallidinogenase for Injection"]}],"interventions":[{"type":"DRUG","name":"Human Urinary Kallidinogenase for Injection","description":"Patients need to complete laboratory tests within a specified time and to complete the experimental requirements of medication time","armGroupLabels":["Control group","Treatment group"],"otherNames":["KLK"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"the decrease of National Institute of Health stroke scale(NIHSS)","timeFrame":"14 Days"}],"secondaryOutcomes":[{"measure":"the Barthel Index","timeFrame":"90 Days"},{"measure":"the Modified Rankin Scale","timeFrame":"90 Days"},{"measure":"change of the National Institute of Health stroke scale","timeFrame":"8 Days"},{"measure":"the composite of ischemic vascular events","description":"ischemic stroke, MI, or ischemic vascular death","timeFrame":"90 Days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age 18 to 80 years old;\n2. First time diagnosed or have history of acute anterior circulation cerebral infarction without serious sequelae (mRS = 0-2);\n3. Acute anterior circulation cerebral infarction with large artery atherosclerotic etiology;\n4. Ability to randomize within 48 h of time last known free of new ischemic symptoms.\n5. National Institute of Health stroke scale(NIHSS) ranges from 7 to 22;\n6. signed written informed consent.\n\nExclusion Criteria:\n\n1. Cerebral CT shows cerebral hemorrhage disease: cerebral hemorrhage, subarachnoid hemorrhage, etc.;\n2. Transient ischemic attack;\n3. Serious disturbance of consciousness: Glasgow Coma ScaleGCS（GCS）≤8;\n4. Combined angiotensin-converting enzyme inhibitor(ACEI) less than 5 half-time (according to its instruction), or need to be treated with ACEI;\n5. Past or present suffering from hemorrhagic tendency of the disease;\n6. The investigator in consideration of the other condition that the patients doesn't fit to participate in this clinical study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Huisheng Chen","role":"CONTACT","phone":"86-24-28897511","email":"chszh@aliyun.com"},{"name":"zhonghe Zhou","role":"CONTACT","phone":"86-24-28897511","email":"Zhouz.h@tom.com"}],"overallOfficials":[{"name":"Huisheng Chen","affiliation":"General Hospital of Shenyang Military Region","role":"STUDY_CHAIR"}],"locations":[{"facility":"General hospital of shenyang military region","status":"RECRUITING","city":"Shenyang","state":"Liaoning","zip":"110840","country":"China","contacts":[{"name":"Hou Xiaowen, Master","role":"CONTACT","phone":"862428897511","phoneExt":"15840240196","email":"sophia_hxw@163.com"}],"geoPoint":{"lat":41.79222,"lon":123.43278}}]},"referencesModule":{"references":[{"pmid":"14698996","type":"BACKGROUND","citation":"Xia CF, Yin H, Borlongan CV, Chao L, Chao J. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension. 2004 Feb;43(2):452-9. doi: 10.1161/01.HYP.0000110905.29389.e5. Epub 2003 Dec 29."},{"pmid":"16534002","type":"BACKGROUND","citation":"Xia CF, Smith RS Jr, Shen B, Yang ZR, Borlongan CV, Chao L, Chao J. Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension. 2006 Apr;47(4):752-61. doi: 10.1161/01.HYP.0000214867.35632.0e. Epub 2006 Mar 13."},{"pmid":"16454654","type":"BACKGROUND","citation":"Xia CF, Yin H, Yao YY, Borlongan CV, Chao L, Chao J. Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther. 2006 Feb;17(2):206-19. doi: 10.1089/hum.2006.17.206."},{"pmid":"20179726","type":"BACKGROUND","citation":"Chen ZB, Huang DQ, Niu FN, Zhang X, Li EG, Xu Y. Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-kappaB. J Cereb Blood Flow Metab. 2010 Jul;30(7):1356-65. doi: 10.1038/jcbfm.2010.19. Epub 2010 Feb 24."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"After the completion of clinical trials ，Through the article published and upload data 。"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007238","term":"Infarction"}],"ancestors":[{"id":"D000007511","term":"Ischemia"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000009336","term":"Necrosis"},{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","asFound":"Infarction","relevance":"HIGH"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Cerebral Infarction","relevance":"HIGH"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000007610","term":"Kallikreins"}],"ancestors":[{"id":"D000003029","term":"Coagulants"},{"id":"D000005303","term":"Fertility Agents, Male"},{"id":"D000005299","term":"Fertility Agents"},{"id":"D000012102","term":"Reproductive Control Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M10328","name":"Kallikreins","asFound":"eNOS","relevance":"HIGH"},{"id":"M5949","name":"Coagulants","relevance":"LOW"}],"browseBranches":[{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"Repr","name":"Reproductive Control Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}